Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
:TOVX
Total Valuation
Theriva Biologics has a market cap or net worth of $4.57M. The enterprise value is -$8.57M.
Market Cap$4.57M
Enterprise Value-$8.57M
Share Statistics
Theriva Biologics has 8,186,989 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,186,989
Owned by Insiders5.46%
Owned by Institutions3.26%
Financial Efficiency
Theriva Biologics’s return on equity (ROE) is -1.35 and return on invested capital (ROIC) is -92.88%.
Return on Equity (ROE)-1.35
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-92.88%
Return on Capital Employed (ROCE)-0.95
Revenue Per Employee0.00
Profits Per Employee-1.28M
Employee Count20
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Theriva Biologics is -0.09. Theriva Biologics’s PEG ratio is >-0.01.
PE Ratio-0.09
PS Ratio0.00
PB Ratio0.04
Price to Fair Value0.12
Price to FCF-0.09
Price to Operating Cash Flow-0.04
PEG Ratio>-0.01
Income Statement
In the last 12 months, Theriva Biologics had revenue of 0.00 and earned -25.65M in profits. Earnings per share was -19.03.
Revenue0.00
Gross Profit0.00
Operating Income-26.35M
Pretax Income-25.65M
Net Income-25.65M
EBITDA-25.52M
Earnings Per Share (EPS)-19.03
Cash Flow
In the last 12 months, operating cash flow was -16.94M and capital expenditures -1.00K, giving a free cash flow of -16.94M billion.
Operating Cash Flow-16.94M
Free Cash Flow-16.94M
Free Cash Flow per Share-2.07
Dividends & Yields
Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change-93.95%
50-Day Moving Average1.15
200-Day Moving Average1.94
Relative Strength Index (RSI)25.47
Average Volume (3m)1.77M
Important Dates
Theriva Biologics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Theriva Biologics as a current ratio of 2.15, with Debt / Equity ratio of 8.21%
Current Ratio2.15
Quick Ratio2.15
Debt to Market Cap0.29
Net Debt to EBITDA0.39
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Theriva Biologics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Theriva Biologics EV to EBITDA ratio is 0.30, with an EV/FCF ratio of 0.45.
EV to Sales0.00
EV to EBITDA0.30
EV to Free Cash Flow0.45
EV to Operating Cash Flow0.45
Balance Sheet
Theriva Biologics has $11.61M in cash and marketable securities with $1.56M in debt, giving a net cash position of -$10.04M billion.
Cash & Marketable Securities$11.61M
Total Debt$1.56M
Net Cash-$10.04M
Net Cash Per Share-$1.23
Tangible Book Value Per Share$1.27
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Theriva Biologics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside1150.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast6.87%